Aurelio Cervera, MD
Clinical Cardiac Electrophysiology · Lubbock, TXNPI 1083833891
Payments from drug & device makers
Across 394 payments — averaging $32.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$3K
- Boston Scientific$2K
- Johnson & Johnson$655
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$479
- Novartis$186
- plus $2K from 27 others
What the payments were for
- Travel & lodging$3,36526%
- Food & beverage$9,58474%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 131 | $5,470 |
| Medtronic(2 entities) | 40 | $2,874 |
| Boston Scientific | 37 | $1,527 |
| Johnson & Johnson | 43 | $655 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 48 | $479 |
| Novartis | 8 | $186 |
| Sanofi-aventis U.S. LLC | 13 | $184 |
| Amgen | 12 | $174 |
| Pfizer | 12 | $174 |
| E.r. Squibb & Sons, L.L.C. | 10 | $155 |
| Cvrx, Inc. | 1 | $131 |
| AstraZeneca | 3 | $127 |
| Endologix LLC | 1 | $86 |
| Philips North America LLC | 2 | $76 |
| Bayer | 4 | $74 |
| Alnylam Pharmaceuticals Inc. | 3 | $71 |
| Novo Nordisk | 3 | $68 |
| Boehringer Ingelheim | 4 | $64 |
| Cardiva Medical, Inc. | 3 | $63 |
| Innovation Technologies Inc | 1 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Kaneka Medical America LLC | 1 | $36 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Cordis US CORP. | 1 | $26 |
| Stryker | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $20 |
| Braemar Manufacturing, LLC | 1 | $18 |
| Cook Medical LLC | 1 | $16 |
| Canon Medical Systems USA, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- POLARx$828
- ADVISOR$646
- ENSITE$409
- EnSite Precision Cardiac Mapping System$352
- Confirm Rx$333
- ENSITE PRECISION$328
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$238
- AMPLATZER$155
- VANTAGEVIEW$155
- OPTIS$140
- PulseSelect$137
- AMPLATZER Occluders$135
- Advisa$132
- Barostim Neo System$131
- Ensite Cardiac Mapping System$121
- DRAGONFLY OPSTAR$120
- HeartMate 3 Left Ventricular Assist Device$113
- HeartMate 3 Left Ventricular Dev$108
- Accent Pacemaker$105
How this compares
$12,988 in reported general payments places this provider in the 20th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 691 | $704,983 |
| XareltoRivaroxaban | 436 | $402,975 |
| MultaqDronedarone Hcl | 293 | $351,558 |
| EntrestoSacubitril/Valsartan | 84 | $108,979 |
| BrilintaTicagrelor | 30 | $29,712 |
| Repatha SureclickEvolocumab | 26 | $14,218 |
| Metoprolol Succinate | 851 | $13,682 |
| Amiodarone Hcl | 398 | $7,666 |
| CorlanorIvabradine Hcl | 13 | $7,653 |
| Repatha SyringeEvolocumab | 13 | $7,027 |
| ClopidogrelClopidogrel Bisulfate | 594 | $6,685 |
| Mexiletine Hcl | 77 | $5,697 |
| SotalolSotalol Hcl | 185 | $3,403 |
| Rosuvastatin Calcium | 50 | $3,316 |
| Potassium Chloride | 143 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $174 | $704,983691 claims |
| Johnson & JohnsonXarelto | $655 | $402,975436 claims |
| Sanofi-aventis U.S. LLCMultaq | $184 | $351,558293 claims |
| NovartisEntresto | $186 | $108,97984 claims |
| AstraZenecaBrilinta | $127 | $29,71230 claims |
| AmgenCorlanor | $174 | $7,65313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Lubbock
- Andrea NataleAustin$7.8M
- George ManoukianShenandoah$3.2M
- Rodney HortonAustin$2.5M
- Stanislav WeinerLongview$2.4M
- Michael DelaughterBedford$2.1M
- James DevillePlano$1.5M
- Robert CanbyAustin$1.5M
- Amin Al-AhmadAustin$1.4M
- Theodore TakataFort Worth$1.4M
- Miguel ValderrabanoHouston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.